Study results by Moreland, et al comparing febuxostat with allopurinol in Patients with hyperuricemia and gout are now published (N Engl J Med 353: 2505-2507). In this multicenter study, 760 patients received either febuxostat (80mg or 120mg) or allopurinol (300mg). 53% and 62% of patients receiving 80mg and 120mg, respectively, achieved serum urate concentration levels of less than 360 mmol perliter compared to 21% of patients receiving allopurinol. These data were previously reported at the 2004 American Rheumatology meeting.
About Arthritis Center
Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.